BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Invus

BioCentury | Apr 4, 2025
Finance

Isomorphic’s $600M funding among four megarounds: Finance Report

Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Mar 5, 2025
Emerging Company Profile

Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy

With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Feb 20, 2025
Finance

Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report

Plus fundings around the globe for Eg 427, Atrandi and Reverb
BioCentury | Dec 20, 2024
Emerging Company Profile

City: Taking RNAi beyond the liver

Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
BioCentury | Dec 19, 2024
Emerging Company Profile

Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2

Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Dec 13, 2024
Finance

Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera

In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Oct 19, 2024
Finance

Cash raises for Inventiva, Akeso, Capricor

Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
BioCentury | Oct 11, 2024
Finance

City is location of Maraganore’s next RNAi play

BioCentury’s latest Venture Report includes rounds for Judo, Purespring, Basecamp, Arda and more
BioCentury | Aug 15, 2024
Finance

Venture Report: Halda bringing RIPTACs into clinic with crossover round

Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis
BioCentury | Jul 18, 2024
Finance

Venture Report: Five biotechs raise nearly $800M in two-day flurry 

Plus: New capital for CytoReason, Truvian and Renalys
Items per page:
1 - 10 of 212
Help Center
Username
Request Training
Submit Data Correction
Ask a Question